- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03534609
Lutronic Genius System for Neck Treatment
January 10, 2020 updated by: LUTRONIC Corporation
Exploratory Evaluation of the Lutronic Genius System for Treatment of the Neck
The Genius system is substantially equivalent to the Infini device (K121481).
The study is a prospective, multi-site, non-randomized study of up to 30 treated subjects presenting for treatment of mild to moderate lines, wrinkles, textural concerns, and/or skin laxity of the neck.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
At enrollment, standardized baseline/pretreatment 2D and 3D images will be obtained from each subject.
Study subjects will receive three neck treatments completed 30 days apart.
Subjects will be contacted via a phone call 3 days following each treatment to assess for adverse events and expected treatment effects.
Effectiveness assessments will occur prior to Treatments #2 and #3, and a follow-up visit will be completed at 90 days following Treatment #3.
Each assessment visit will include efficacy, adverse events, and expected treatment effects assessments, and post-treatment 2D and 3D digital images will be captured.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- Laser and Skin Surgery Center of New York
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, age 18 years and older.
- Subject in good health.
- Fitzpatrick Skin Type I to VI.
- Mild to moderate lines, wrinkles, textural concerns, and/or skin laxity of the neck.
- Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
- Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
- Post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.
- Absence of physical or psychological conditions unacceptable to the investigator.
- Willingness and ability to provide written consent for study-required photography and adherence to photography procedures (i.e., removal of jewelry and makeup).
- Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure.
Exclusion Criteria:
- Presence of an active skin condition or infection in the treatment area such as sores, Psoriasis, eczema, rash, severe active inflammatory acne or oral herpes simplex breakout.
- History of skin disorders, keloid scarring, and/or abnormal wound healing.
- Open wounds or lesions in the area(s) to be treated.
- Inability to understand the protocol or to give informed consent.
- History of chronic drug or alcohol abuse.
- History of vascular disease.
- History of bleeding disorders.
- BMI equal to or greater than 30.
- Subjects who are pregnant, nursing, or anticipate a pregnancy during the length of the trial.
- Subjects with current skin cancer or other malignant disease including pre-malignant moles.
- Poorly controlled medical condition that could compromise wound healing or increase risk of infection such as an impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications, radiation therapy, or chemotherapy.
- Subjects with implanted medical devices: pacemaker, cardioverts, superficial metal within the treatment area, and other implantable devices or synthetic fillers.
- Subjects with sensitivity or allergy to gold.
- Subjects with sensitivity or allergy to local anesthetics such as lidocaine or tetracaine.
- Concurrent enrollment in any study involving the use of investigational devices or drugs.
- History of surgical or cosmetic treatments in the area(s) to be treated within the past six months.
History or current use of the following prescription medications:
- Daily anticoagulants, aspirin, iron supplements, herbal supplements such as ginkgo, ginseng or garlic within the past two weeks;
- Topical retinoid within the past one week; and
- Psychiatric drugs that in the investigators opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Genius System Neck Treatment
Lutronic Genius System treatment of lines, wrinkles, and texture concerns on the neck.
|
Treatment of the neck using the Lutronic Genius System
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Masked qualitative assessment of improvement
Time Frame: From baseline to 90 days following the last treatment
|
An assessment of paired pre- and post-treatment photographs will be conducted by blinded assessors evaluating for improvement in neck appearance from pre- to post-treatment.
The assessors choose the photo they believe to be the post-treatment photo, i.e., Left photo or Right photo.
|
From baseline to 90 days following the last treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician aesthetic improvement
Time Frame: From baseline to Days 90 following the last study treatment.
|
Overall aesthetic improvement based on completion of the Clinician Global Aesthetic Improvement Scale, a 5-point scale (0-4) that rates global aesthetic improvement from the pre-treatment appearance with 4 being 'Very Much Improved' and 0 being 'Worse'.
The scale will be administered based on a live assessment of the subject while referring to the subject's pre-treatment photographs, and based on a comparison of the subject's pre-treatment photographs to the Day 90 follow-up photographs.
|
From baseline to Days 90 following the last study treatment.
|
Subject aesthetic improvement
Time Frame: From baseline to Days 90 following the last study treatment.
|
Overall aesthetic improvement based on completion of the Subject Global Aesthetic Improvement Scale, a 5-point scale (0-4) that rates global aesthetic improvement from the pre-treatment appearance with 4 being 'Very Much Improved' and 0 being 'Worse'.
Subjects will complete the scale based on a live assessment while referring to a hand mirror and their pre-treatment photographs, and based on a comparison of their pre-treatment photographs to their Day 90 follow-up photographs.
|
From baseline to Days 90 following the last study treatment.
|
Patient Satisfaction
Time Frame: From baseline to 90 days following the last study treatment
|
Patient satisfaction will be evaluated based on subjects' completion of a patient satisfaction questionnaire while referring to a hand mirror and their pre-treatment and their Day 90 follow-up photographs.
|
From baseline to 90 days following the last study treatment
|
Treatment-related pain
Time Frame: For the duration of each study treatment which typically can last up to approximately 90 minutes.
|
During each study treatment, subjects' pain levels will be monitored using a validated Numeric Rating Scale (0-10), with 0 being 'No Pain' and 10 being 'Worse Possible Pain'.
|
For the duration of each study treatment which typically can last up to approximately 90 minutes.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Kari Larson, MBA, Sponsor GmbH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 27, 2018
Primary Completion (Actual)
January 16, 2019
Study Completion (Actual)
January 10, 2020
Study Registration Dates
First Submitted
April 16, 2018
First Submitted That Met QC Criteria
May 11, 2018
First Posted (Actual)
May 23, 2018
Study Record Updates
Last Update Posted (Actual)
January 13, 2020
Last Update Submitted That Met QC Criteria
January 10, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L18000
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wrinkle
-
Physicians Laser and Dermatology InstituteRecruiting
-
Shanghai Dermatology HospitalRecruiting
-
Integrative Skin Science and ResearchActeraActive, not recruiting
-
Cynosure, Inc.Terminated
-
Saie BeautyCompleted
-
HaEmek Medical Center, IsraelUnknown
-
Galderma R&DCompleted
-
Universiti Sains MalaysiaMalaysia Palm Oil Board; Avantsar Sdn. Bhd.Terminated
-
Integrative Skin Science and ResearchArbonneActive, not recruiting
Clinical Trials on Lutronic Genius System
-
LUTRONIC CorporationCompletedFace and Neck Wrinkles, Texture, PigmentationUnited States
-
Aarhus University HospitalBispebjerg HospitalUnknownAcne Scars - Mixed Atrophic and HypertrophicDenmark
-
Hologic Deutschland GmbHRecruitingCervical Cancer ScreeningGermany
-
Cosmo Artificial Intelligence-AI LtdCompletedArtificial IntelligenceItaly
-
Clinique Paris-BercyCompletedColonic Polyp | Artificial Intelligence | Colonic Neoplasms | Colonoscopy | Colonic AdenomaFrance
-
Hologic Deutschland GmbHCompletedCervical Cancer ScreeningGermany
-
Hospital Universitario La FeMedtronic; European Society of Gastrointestinal EndoscopyRecruiting
-
Nuovo Regina Margherita HospitalCompleted
-
Centre hospitalier de l'Université de Montréal...University of British Columbia; McGill University; Université de Sherbrooke; University...RecruitingArtificial IntelligenceCanada
-
Marshall UniversityEnrolling by invitationColon Cancer Screening | Colon Cancer SurveillanceUnited States